Literature DB >> 33443625

[MDVI patients - Multiply disabled visually impaired : On the situation of the child, parents and ophthalmologist with MDVI children].

Barbara Käsmann-Kellner1, Berthold Seitz2.   

Abstract

Functional visual perception significantly contributes to the child's development and consists of much more than just visual acuity and the visual field. It includes cognitive interpretation of visual stimuli and runs along the temporal and parietal pathways of visual processing. Central visual impairment (CVI) usually affects otherwise healthy children with often good visual acuity, whereas the multiply disabled visually impaired (MDVI) have visual impairment and multiple disabilities. In MDVI patients an ocular and/or CVI can be present. The examination of MDVI patients poses a great challenge for the ophthalmologist and reflective visual test procedures should also be used. Particular attention should be paid to refraction and accommodation. The main ocular diagnosis in MDVI is optic atrophy and the general diagnoses are dominated by sequelae of premature birth, often in combination with spasticity and epilepsy. Early intervention is essential and is independent of the underlying diagnoses.

Entities:  

Keywords:  Central visual impairment; Multiple disabilities; Optic atrophy; Refraction; Visual perception

Mesh:

Year:  2021        PMID: 33443625     DOI: 10.1007/s00347-020-01300-5

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  17 in total

1.  Low grating acuity in slow readers with normal recognition acuity.

Authors:  Lea Hyvärinen
Journal:  Acta Ophthalmol       Date:  2014-03-19       Impact factor: 3.761

2.  Ophthalmologic outcome at 30 months' corrected age of a prospective Swedish cohort of children born before 27 weeks of gestation: the extremely preterm infants in sweden study.

Authors:  Gerd E Holmström; Karin Källen; Ann Hellström; Peter G Jakobsson; Fredrik Serenius; Karin Stjernqvist; Kristina Tornqvist
Journal:  JAMA Ophthalmol       Date:  2014-02       Impact factor: 7.389

3.  6,220 institutionalised people with intellectual disability referred for visual assessment between 1993 and 2003: overview and trends.

Authors:  C E D van Isterdael; J S Stilma; P D Bezemer; N T Tijmes
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638

4.  [Eye and general illnesses in the public school for blind and visually handicapped students in Saarland. Developments in the last 20 years].

Authors:  B Käsmann-Kellner; K Hille; B Pfau; K W Ruprecht
Journal:  Ophthalmologe       Date:  1998-01       Impact factor: 1.059

5.  Rehabilitation of cortical visual impairment in children.

Authors:  Denise E Malkowicz; Ginette Myers; Gerry Leisman
Journal:  Int J Neurosci       Date:  2006-09       Impact factor: 2.292

6.  Visual impairment in children born prematurely from 1972 through 1989.

Authors:  Sirkka-Liisa Rudanko; Vineta Fellman; Leila Laatikainen
Journal:  Ophthalmology       Date:  2003-08       Impact factor: 12.079

7.  Cortical visual impairment: etiology, associated findings, and prognosis in a tertiary care setting.

Authors:  Vijay Khetpal; Sean P Donahue
Journal:  J AAPOS       Date:  2007-04-24       Impact factor: 1.220

8.  [Prevalence of optic atrophy and associated ocular and systemic diseases in a department of paediatric ophthalmology].

Authors:  Christian Denne; Barbara Käsmann-Kellner; Klaus W Ruprecht
Journal:  Klin Monbl Augenheilkd       Date:  2003-11       Impact factor: 0.700

9.  Visual, musculoskeletal and balance symptoms in individuals with visual impairment.

Authors:  Christina Zetterlund; Lars-Olov Lundqvist; Hans Olof Richter
Journal:  Clin Exp Optom       Date:  2018-06-25       Impact factor: 2.742

10.  Cerebral visual impairment is a major cause of profound visual impairment in children aged less than 3 years: A study from tertiary eye care center in South India.

Authors:  Niranjan K Pehere; Asa Narasaiah; Gordon N Dutton
Journal:  Indian J Ophthalmol       Date:  2019-10       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.